The present study showed that pathways in cancer, human cytomegalovirus infection, prostate cancer and chronic myeloid leukemia, and AGE-RAGE signaling pathway in diabetic complications might be involved in the effect of key therapeutic targets of α-MG. Here, AMELX is linked to chronic myelogenous leukemia, BCR-ABL1 positive.